Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|JNJ-64619178||JNJ64619178|JNJ 64619178||JNJ-64619178 is a PRMT5 inhibitor that binds to and inhibits the S-adenosylmethionine (SAM) and substrate-binding regions of the PRMT5/MEP50 complex, potentially reducing dimethylation of target proteins such as SMD1/3 and resulting in tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 4859).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung cancer||not applicable||JNJ-64619178||Preclinical - Cell line xenograft||Actionable||In a preclinical study, JNJ-64619178 treatment inhibited tumor growth and induced regression in cell line xenograft models of small cell and non-small cell lung carcinoma (Cancer Res 2018;78(13 Suppl):Abstract nr 4859).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03573310||Phase I||JNJ-64619178||A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS||Recruiting|